Background <p>Immune checkpoint inhibitors achieve high response rates in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL), but few treatment options are available for patients who experience failure after PD-1/PD-L1 blockade. T cell immunoglobulin and mucin-domain containing-3, a key mediator of immune escape from PD-1/PD-L1 inhibition, is targeted by TQB2618, a humanized IgG<sub>4</sub> monoclonal antibody. This phase Ib study aimed…
Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial
Journal for ImmunoTherapy of Cancer | | Hong, H., Chen, Z., Cui, J., Zhang, Q., Li, P., Tao, R., Huang, H., Wang, B., Li, W., Wu, H., Wei, J., Su, L., Zhang, Z., Zhong, M., Wang, H., Wang, C., Zhou, H., Wang, J., Dong, M., Lin, T.
Topics: blood-cancer, cervical-cancer, immunotherapy, targeted-therapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer